Meeting
2018 ASCO Annual Meeting
Prospective, multinational, observational study of real-world treatment outcomes with pazopanib in patients with advanced or metastatic renal cell carcinoma (PRINCIPAL Study).
Authors
Manuela Schmidinger
Medical University of Vienna, Vienna, Austria
Manuela Schmidinger , Giuseppe Procopio , Robert E. Hawkins , Angel Rodriguez Sanchez , Sergio Vazquez , Narayanan Srihari , Haralabos Kalofonos , Aristotelis Bamias , Petri Bono , Chaitali Babanrao Pisal , Yulia Hirschberg , Luca Dezzani , Qasim Iftikhar Ahmad , Eric Jonasch
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary (Nonprostate) Cancer
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Kidney Cancer
Clinical Trial Registration Number
NCT01649778
Citation
J Clin Oncol 36, 2018 (suppl; abstr 4574)
DOI
10.1200/JCO.2018.36.15_suppl.4574
Abstract #
4574
Poster Bd #
400
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
Cabozantinib + nivolumab in adult patients with advanced or metastatic renal cell carcinoma: A retrospective, non-interventional study in a real-world cohort.
First Author: Thomas Hilser
Poster
2020 Genitourinary Cancers Symposium
Prospective observational study on pazopanib in patients treated for advanced/metastatic renal cell carcinoma (RCC): APOLON Study.
First Author: Philippe Barthelemy
Poster
2018 ASCO Annual Meeting
Comparison of clinical outcomes with first-line pazopanib in clinical trial eligible and non-clinical trial eligible patients with renal cell carcinoma.
First Author: Eric Jonasch
Poster
2014 ASCO Annual Meeting
Principal: A prospective observational study of real-world treatment patterns and treatment outcomes in patients with advanced or metastatic renal cell carcinoma (mRCC) receiving pazopanib.
First Author: Aristotelis Bamias